|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Hormone Replacement Therapy Can Decrease Peripheral Arterial Disease, New York University Study
6/17/2011 6:49:38 AM
A new study presented at the 65th Vascular Annual Meeting® of the Society of Vascular Surgery® found that the use of HRT in postmenopausal women is associated with a significant reduction in the prevalence of peripheral arterial disease (PAD). According to researchers from the Department of Vascular Surgery at New York University Medical School in New York City, this association was significant even in postmenopausal female patients with known atherosclerotic risk factors.
“This data has important implications with regard to a possible protective effect of HRT on atherosclerotic conditions, particularly in patients at higher risk for these conditions due to medical co-morbidities,” said Caron B. Rockman, MD, vascular and endovascular surgeon. “Our initial task was to gather information from a prospective database of patients who underwent vascular screening to identify them as postmenopausal. A questionnaire was used to determine their use of HRT. Peripheral artery disease was noted if their ankle-brachial index was less or equal to 0.9.”
Analysis was performed on 847,982 postmenopausal women; 433,178 (51.1 percent) reported having used HRT. The HRT patients were slightly older than patients who had not used HRT (64.7 years vs. 64.3 years). When HRT patients were compared to non-HRT patients, they were significantly more likely to be Caucasian (93.6 percent vs. 83.3 percent), to have smoked cigarettes (42.8 percent vs. 40.6 percent), to have hypertension (47.9 percent vs. 45.1 percent) and to have hypercholesterolemia (55.0 percent vs. 51.5 percent).
Despite the increased prevalence of several atherosclerotic risk factors among women who used HRT, researchers found that they were significantly less likely to have PAD (3.3 percent vs. 4.1 percent). Multivariate analysis confirmed that HRT was independently associated with a decreased risk of PAD (OR 0.8, 95 percent CI 0.78-0.82). In addition, HRT patients were less likely to have diabetes (8.6 percent vs. 10.1 percent).
“The significant effect of HRT on the prevalence for PAD was maintained in the patients with existing atherosclerotic risk factors,” added Dr. Rockman, “and in postmenopausal women with either a smoking history, hypertension, hypercholesterolemia, or diabetes, the odds ratio of HRT use with regard to PAD remained 0.8.” This analysis of nearly 850,000 post-menopausal women clearly demonstrates an association between the use of hormone replacement therapy and a lower risk of having peripheral arterial occlusive disease.
About the Society for Vascular Surgery
The Society for Vascular Surgery® (SVS) is a not-for-profit professional medical society, composed primarily of vascular surgeons, that seeks to advance excellence and innovation in vascular health through education, advocacy, research, and public awareness. SVS is the national advocate for 3,350 specialty-trained vascular surgeons and other medical professionals who are dedicated to the prevention and cure of vascular disease. Visit its Web site at www.VascularWeb.org® and follow SVS on Twitter by searching for VascularHealth or at http://twitter.com/VascularHealth.
|
|
|
|
|
|
|
|
|
|
|